openPR Logo
Press release

Gastric Inhibitory Polypeptide Receptor-Pipeline Review H2 2017

11-23-2017 06:52 PM CET | Health & Medicine

Press release from: ReportsWeb

Gastric Inhibitory Polypeptide Receptor-Pipeline Review H2

The report 'Gastric Inhibitory Polypeptide Receptor-Pipeline Review, H2 2017' outlays comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

According to the recently published report 'Gastric Inhibitory Polypeptide Receptor-Pipeline Review, H2 2017'; Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

Get Sample Copy of Report@ http://www.reportsweb.com/inquiry&RW00011030811/sample

Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)-Glucose-dependent insulinotropic polypeptide receptor (GIPR) is a transmembrane protein in humans which is encoded by the GIPR gene. GIPR is expressed on pancreatic beta-cells which lead to activation and release of insulin. The transcription of this protein is positively controlled by glucose molecules. GIPR is expressed in higher levels when glucose is in higher concentration. The ligand which binds to GIPR is glucose-dependent insulinotropic polypeptide (GIP) also known as gastric inhibitory polypeptide. Glucose-dependent insulinotropic polypeptide is released from the duodenum and small intestine. GIP binds to GIPR though hydrophobic interactions and triggering activation of G protein-coupled receptors, which in turn causes an enzymatic cascade resulting in the increased secretion of insulin. Endogeonous ligands for the receptor include oleylethanolamide and lysophosphatidylcholine. The cause of type 2 diabetes is due to the inability of GIP to bind properly to GIPR.

It also reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Gastrointestinal which include indications Type 2 Diabetes, Obesity, Alzheimer's Disease, Non-Alcoholic Steatohepatitis (NASH) and Parkinson's Disease.

Read More Information and TOC of the Report@http://www.reportsweb.com/gastric-inhibitory-polypeptide-receptor-pipeline-review-h2-2017

-The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR)
-The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects
-The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

Buy This Report@ http://www.reportsweb.com/buy&RW00011030811/buy/3500

-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics

About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gastric Inhibitory Polypeptide Receptor-Pipeline Review H2 2017 here

News-ID: 830981 • Views: 302

More Releases from ReportsWeb

North America: Smart Airport Market Overall Study Report 2020-2026| Amadeus IT G …
The "Global North America Smart Airport Market: 2020" Industry Report is a professional and in-depth study on the current state of the North America Smart Airport Market by PMR. The North America Smart Airport market is supposed to demonstrate a considerable growth during the forecast period of 2020 - 2026. The company profiles of all the key players and brands that are dominating the market have been given in this
Marine Biotechnology Market Future Forecast 2018-2026 by Leading Companies such …
ReportsWeb.com has announced the addition of the “Marine Biotechnology-Global Market Outlook 2017-2026” The report classifies the global Marine Biotechnology Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. According to Publisher, the Global Marine Biotechnology Market is accounted for $3.93 billion in 2017 and is expected to reach $8.74 billion by 2026 growing at a CAGR of 9.3% during
Anti-Counterfeiting Packaging Market Growth Opportunities and Emerging Trends by …
ReportsWeb.com has announced the addition of the “Anti-Counterfeiting Packaging-Global Market Outlook 2017-2026” The report classifies the global Anti-Counterfeiting Packaging Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. According to Publisher, the Global Anti-Counterfeiting Packaging Market is accounted for $112.16 billion in 2017 and is expected to reach $427.96 billion by 2026 growing at a CAGR of 16.0% during
Solar Photovoltaic in Italy Market Outlook to 2030 | Company Profiles (Tozzi Hol …
Solar Photovoltaic (PV) in Italy, Market Outlook to 2030, Update 2018-Capacity, Generation, Investment Trends, Regulations and Company Profiles Summary "Solar Photovoltaic (PV) in Italy, Market Outlook to 2030, Update 2018-Capacity, Generation, Investment Trends, Regulations and Company Profiles", is the latest report from Publisher, the industry analysis specialists that offer comprehensive information and understanding of the Solar Photovoltaic (PV) market in Italy. The report provides in depth analysis on global renewable power market and

All 5 Releases


More Releases for Polypeptide

Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages
Polypeptide Market Discern Magnified Growth By 2028
With an increasing number of patients diagnosed with cancer, many pharmaceutical companies are conducting intensive research to discover effective anti-cancer drugs. The World Health Organization (WHO), cancer was the second leading cause of death, killing over 8.8 million people across the globe. 70% patients in low- or middle-income countries, who are diagnosed with cancer succumb to death. It generates needs for an effective oncology medicine that can reduce the number
Polypeptide Market Analysis , Trends, Opportunity, 2018 to 2028
Global Polypeptides Market: Overview Polypeptides, the organic polymers containing a large number of amino-acids bonded together on the form of a chain, represent essential portions of proteins with unique pharmacokinetic properties as compared to small molecule drugs and large proteins. Polypeptides play a crucial role in modulating cellular functions and coordinating intercellular communications. There are hardly any other classes of bio-molecules that offer as much chemical diversity as polypeptides do. Researchers have
Islet Amyloid Polypeptide Market Trends & Forecast to 2022
HTF MI published a new industry research that focuses on Islet Amyloid Polypeptide market and delivers in-depth market analysis and future prospects of Global Islet Amyloid Polypeptide market. The study covers significant data which makes the research document a handy resource for managers, analysts, industry experts and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges. The
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polype …
ReportsWorldwide has announced the addition of a new report title Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary According to the recently published report 'Gastric Inhibitory Polypeptide Receptor - Pipeline Review, H2 2017'; Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 14 molecules. Out of which
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polype …
Market Research Hub (MRH) added a new research report to its vast database titled “Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Pipeline Review, H2 2017” Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1313667 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Glucose-dependent insulinotropic polypeptide